Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 410246, 4 pages
http://dx.doi.org/10.1155/2012/410246
Research Article

Radical Prostatectomy: An Option for High-Risk Prostate Cancer

Department of Urology, Fulda Civic Hospital, Pacelliallee 4, 36043 Fulda, Germany

Received 21 April 2011; Revised 26 May 2011; Accepted 21 July 2011

Academic Editor: Steven Joniau

Copyright © 2012 S. Rausch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R.J. Karnes, T. Hatano, M. L. Blute et al., “Radical prostatectomy for high-risk prostate cancer,” Current Opinion in Urology, vol. 40, no. 1, pp. 3–9, 2010. View at Publisher · View at Google Scholar
  2. A. V. D'Amico, R. Whittington, B. S. Malkowicz et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” The Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Boorjian, R. J. Karnes, P. L. Crispen et al., “The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy,” Journal of Urology, vol. 181, no. 1, pp. 95–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Cooperberg, J. M. Broering, and P. R. Carroll, “Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis,” Journal of the National Cancer Institute, vol. 101, no. 12, pp. 878–887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Spahn, S. Joniau, P. Gontero et al., “Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients,” European Urology, vol. 58, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. B. A. Inman, J. D. Davies, L. J. Rangel et al., “Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL,” Cancer, vol. 113, no. 7, pp. 1544–1551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. May, S. Gunia, C. Helke et al., “How far is the preoperative Kattan nomogram applicable for the prediction of recurrence after prostatectomy in patients presenting with PSA levels of more than 20 ng/ml? A validation study,” Urologia Internationalis, vol. 77, no. 3, pp. 222–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Gontero, M. Spahn, B. Tombal et al., “Is there a prostate-specific antigen upper limit for radical prostatectomy?” BJU International, vol. 108, no. 7, pp. 1093–1100, 2011. View at Publisher · View at Google Scholar
  9. M. V. Meng, E. P. Elkin, D. M. Latini, J. DuChane, and P. R. Carroll, “Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE),” Journal of Urology, vol. 173, no. 5, pp. 1557–1561, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Walz, S. Joniau, F. K. Chun et al., “Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy,” British Journal of Urology International, vol. 107, no. 5, pp. 765–770, 2011. View at Publisher · View at Google Scholar
  11. H. Zincke, W. Lau, E. Bergstralh, and M. L. Blute, “Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer,” Journal of Urology, vol. 166, no. 6, pp. 2208–2215, 2001. View at Google Scholar · View at Scopus
  12. E. M. Messing, J. Manola, J. Yao et al., “Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy,” Lancet Oncology, vol. 7, no. 6, pp. 472–479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Bolla, H. Van Poppel, L. Collette et al., “Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911),” The Lancet, vol. 366, no. 9485, pp. 572–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Kumar, M. Shelley, C. Harrison, B. Coles, T. J. Wilt, and M. D. Mason, “Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer,” Cochrane Database of Systematic Reviews, no. 4, p. CD006019, 2006. View at Google Scholar · View at Scopus
  15. S. Loeb, N. D. Smith, K. A. Roehl, and W. J. Catalona, “Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer,” Urology, vol. 69, no. 6, pp. 1170–1175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Gontero, G. Marchioro, R. Pisani et al., “Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study,” European Urology, vol. 51, no. 4, pp. 922–930, 2007. View at Google Scholar · View at Scopus